Voyager Therapeutics is a biotechnology company that develops gene therapies and other neurotherapeutics to treat neurological diseases including Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, and other central nervous system disorders. The company's core technology platforms are TRACER, an adeno-associated virus capsid discovery system engineered to cross the blood-brain barrier and deliver therapeutic cargo to the brain, and Voyager NeuroShuttle, a non-viral delivery platform for transporting drugs across the blood-brain barrier. The company generates revenue through partnerships with larger pharmaceutical companies, including upfront payments, milestone payments triggered by clinical and regulatory achievements, royalties on product sales, and research funding reimbursement; partnerships have historically generated hundreds of millions in upfront funding and represent potential for billions in milestone payments and royalties.